Enlivex Therapeutics $ENLV: Dual-Engine Corporate Structure Combines Macrophage Reprogramming Immunotherapy with RAIN Protocol Treasury Strategy CEO Oren Hershkovitz outlines Enlivex's dual-engine corporate model — a structure that combines clinical-stage quality longevity therapeutics with a digital asset treasury anchored in the RAIN decentralized prediction markets protocol. Why investors are watching: - Allocetra Phase IIb trial underway in primary knee OA with FDA clearance; pipeline expanding into basal thumb OA and TMJ OA - $212M PIPE established RAIN as primary reserve asset; exclusive option to acquire up to $918M of RAIN at a fixed price of $0.0033 - RAIN protocol features a 2.5% buyback-and-burn mechanism; active treasury strategy includes staking and governance participation - Two non-correlated value drivers: clinical-stage longevity therapeutics and decentralized forecasting infrastructure Watch the full overview: https://t.co/P3GqdCknZg $ENLV $RAIN $MSTR $MARA $TSLA $SMLR $COIN $FORD $HIVE $EXOD $JNJ $ABBV $MRK